Interestingly when these IDH1 and IDH2 inhibitors were combined with standard chemotherapy in de novo and secondary AML, ivosidenib determined a CR rate of 93% and 73% and enasidenib determined a CR rate of 73% and 63% [118]. Here, IDH2 is linked to acute myeloid leukemia.